View in EDS HTML Full Text PDF Full Text

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.

Saved in:
Bibliographic Details
Title: Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Authors: Mukherjee D; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Romano E; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Walshaw R; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Zeef LAH; Bioinformatics Core Facility, Michael Smith Building, The University of Manchester, Manchester, UK., Banyard A; Mass and Flow Cytometry Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Kitcatt SJ; Scientific Computing Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Cheadle EJ; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Tuomela K; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Pendharkar S; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Al-Deka A; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Salerno B; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Raby S; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Mills IG; Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.; Patrick G. Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK., Honeychurch J; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Illidge TM; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
Source: Oncoimmunology [Oncoimmunology] 2023 Jun 15; Vol. 12 (1), pp. 2223094. Date of Electronic Publication: 2023 Jun 15 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37332616
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mukherjee+D%22">Mukherjee D</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Romano+E%22">Romano E</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Walshaw+R%22">Walshaw R</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Zeef+LAH%22">Zeef LAH</searchLink>; Bioinformatics Core Facility, Michael Smith Building, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Banyard+A%22">Banyard A</searchLink>; Mass and Flow Cytometry Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Kitcatt+SJ%22">Kitcatt SJ</searchLink>; Scientific Computing Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Cheadle+EJ%22">Cheadle EJ</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Tuomela+K%22">Tuomela K</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Pendharkar+S%22">Pendharkar S</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Al-Deka+A%22">Al-Deka A</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Salerno+B%22">Salerno B</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Raby+S%22">Raby S</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Mills+IG%22">Mills IG</searchLink>; Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.; Patrick G. Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK.<br /><searchLink fieldCode="AU" term="%22Honeychurch+J%22">Honeychurch J</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Illidge+TM%22">Illidge TM</searchLink>; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101570526%22">Oncoimmunology</searchLink> [Oncoimmunology] 2023 Jun 15; Vol. 12 (1), pp. 2223094. <i>Date of Electronic Publication: </i>2023 Jun 15 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101570526 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2162-402X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221624011%22">21624011 </searchLink><i>NLM ISO Abbreviation: </i>Oncoimmunology <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37332616
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/2162402X.2023.2223094
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2223094
    Titles:
      – TitleFull: Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mukherjee D
      – PersonEntity:
          Name:
            NameFull: Romano E
      – PersonEntity:
          Name:
            NameFull: Walshaw R
      – PersonEntity:
          Name:
            NameFull: Zeef LAH
      – PersonEntity:
          Name:
            NameFull: Banyard A
      – PersonEntity:
          Name:
            NameFull: Kitcatt SJ
      – PersonEntity:
          Name:
            NameFull: Cheadle EJ
      – PersonEntity:
          Name:
            NameFull: Tuomela K
      – PersonEntity:
          Name:
            NameFull: Pendharkar S
      – PersonEntity:
          Name:
            NameFull: Al-Deka A
      – PersonEntity:
          Name:
            NameFull: Salerno B
      – PersonEntity:
          Name:
            NameFull: Raby S
      – PersonEntity:
          Name:
            NameFull: Mills IG
      – PersonEntity:
          Name:
            NameFull: Honeychurch J
      – PersonEntity:
          Name:
            NameFull: Illidge TM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 06
              Text: 2023 Jun 15
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2162-402X
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Oncoimmunology
              Type: main
ResultId 1